<code id='5C1DCE0A02'></code><style id='5C1DCE0A02'></style>
      • <acronym id='5C1DCE0A02'></acronym>
      <center id='5C1DCE0A02'><center id='5C1DCE0A02'><tfoot id='5C1DCE0A02'></tfoot></center><abbr id='5C1DCE0A02'><dir id='5C1DCE0A02'><tfoot id='5C1DCE0A02'></tfoot><noframes id='5C1DCE0A02'>
      • <optgroup id='5C1DCE0A02'><strike id='5C1DCE0A02'><sup id='5C1DCE0A02'></sup></strike><code id='5C1DCE0A02'></code></optgroup>
        5. <b id='5C1DCE0A02'><label id='5C1DCE0A02'><select id='5C1DCE0A02'><dt id='5C1DCE0A02'><span id='5C1DCE0A02'></span></dt></select></label></b><u id='5C1DCE0A02'></u>
          <i id='5C1DCE0A02'><strike id='5C1DCE0A02'><tt id='5C1DCE0A02'><pre id='5C1DCE0A02'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-10 00:56:51 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：6
                                  
                                    
          
                                   
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe
          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 
          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?
          advertisement
          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          The unintended consequences of overturning Roe v. Wade
                                
                            
          Next article：  
                                      
                                          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles